Výsledky vyhledávání

Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor

Autor: Hiromi, Ozawa, Tomoko, Higuchi, Yukie, Fujimoto, Ayako, Bun, Reiko, Fukui, Haruka, Kanaoka, Masayuki, Nagahashi, Kazuhiro, Kitajima, Koichiro, Yamakado, Yasuo, Miyoshi

Publikováno v: Anticancer Research. 42:4813-4824

Endocrine therapy (ET) with or without CDK4/6 inhibitors is the primary treatment choice for patients with estrogen receptor (ER)-positive and HER2-negative subtype of metastatic breast cancer (MBC). We examined the metabolic parameters identified us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa51cee0fac1924d9fc81927d0c05f28
https://doi.org/10.21873/anticanres.15986

Zobrazit plný text záznamu

Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors

Autor: Haruka, Kanaoka, Masayuki, Nagahashi, Yusa, Atake, Akira, Hattori, Ayako, Bun, Reiko, Fukui, Hiromi, Ozawa, Yukie, Fujimoto, Tomoko, Higuchi, Keiko, Natori, Michiko, Imamura, Keiko, Murase, Yuichi, Takatsuka, Yasuo, Miyoshi

Publikováno v: Anticancer Research. 42:4867-4878

The aim of this study was to elucidate the clinical significance of peripheral blood biomarkers, including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and C-reactive protein (CRP) in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50f426ef64fbd952015faad93b71e572
https://doi.org/10.21873/anticanres.15992

Zobrazit plný text záznamu

Abstract P4-07-26: Clinical impact of tumor infiltrating lymphocytes and neutrophil-lymphocyte ratio in estrogen receptor-positive/HER2-negative breast cancer patients with high 21-gene signature recurrence scores

Autor: Haruka Kanaoka, Masayuki Nagahashi, Eri Ishikawa, Ayako Bun, Reiko Fukui, Hiromi Ozawa, Tomoko Higuchi, Keiko Natori, Michiko Imamura, Yuichi Takatsuka, Yasuo Miyoshi

Publikováno v: Cancer Research. 82:P4-07

Background: Many guidelines recommended multi-gene assays to determine an indication of postoperative chemotherapy for estrogen receptor-positive (ER+)/HER2-negative (HER2−) breast cancer patients. The 21-gene signature assay (Oncotype DX) is one s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::651ed30fa543096fb5b139064347a8fc
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-26

Zobrazit plný text záznamu

Abstract PS4-20: Low levels of interleukin-6 at baseline were significantly associated with improved overall survival of patients treated with eribulin for locally advanced or metastatic breast cancer

Autor: Tomoko Higuchi, Reiko Fukui, Hiromi Ozawa, Michiko Imamura, Yoshimasa Miyagawa, Atsushi Sata, Natsuko Inoue, Ayako Bun, Yasuo Miyoshi, Yukie Fujimoto

Publikováno v: Cancer Research. 81:PS4-20

(Background)Eribulin, a non-taxane inhibitor of microtubule dynamics, is a unique chemotherapy agent for locally advanced or metastatic breast cancer (MBC). The treatment has been demonstrated to extend overall survival (OS) without extending progres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01c2bab4b8009feced6bc8bfecf0905d
https://doi.org/10.1158/1538-7445.sabcs20-ps4-20

Zobrazit plný text záznamu

Abstract P3-08-30: Low levels of metabolic tumor volume at baseline significantly associated with longer progression-free survival in patients with locally advanced or metastatic breast cancer treated with endocrine therapies

Autor: Reiko Fukui, Tomoko Higuchi, Yukie Fujimoto, Atsushi Sata, Ayako Bun, Hiromi Ozawa, Yoshimasa Miyagawa, Michiko Imamura, Kazuhiro Kitajima, Yasuo Miyoshi

Publikováno v: Cancer Research. 80:P3-08

Background Endocrine therapy is an essential treatment choice for patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced and metastatic breast cancers. Although patients with non-vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83e0b762b0bda4b1161ba2f539705225
https://doi.org/10.1158/1538-7445.sabcs19-p3-08-30

Zobrazit plný text záznamu

A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site

Autor: Michiko Imamura, Reiko Fukui, Yukie Fujimoto, Yoshimasa Miyagawa, Tomoko Higuchi, Hiromi Ozawa, Yasuo Miyoshi, Ayako Bun, Atsushi Sata

Publikováno v: Anticancer Research. 39:5653-5662

Background/aim Factors influencing fulvestrant efficacy may be useful in selecting the optimal treatment regimen for postmenopausal Japanese women with metastatic/recurrent HR-positive, HER2-negative breast cancer. Patients and methods We retrospecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37dec94be2459b9344226a2efe7dff86
https://doi.org/10.21873/anticanres.13762

Zobrazit plný text záznamu

Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy

Autor: Yoshimasa Miyagawa, Ayako Bun, Yasuo Miyoshi, Reiko Fukui, Kazuhiro Kitajima, Hiromi Ozawa, Michiko Imamura, Yukie Fujimoto, Koichiro Yamakado, Tomoko Higuchi

Publikováno v: Annals of Surgical Oncology. 26:2175-2183

The usefulness of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography for evaluating the treatment efficacy of breast cancers is well-established; however, the predictive values of parameters such as metabolic tumor volume (MTV) a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af66e50e4fe4a6ee13b354a08f1d4296
https://doi.org/10.1245/s10434-019-07325-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání